Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Biosimilar Eptacog Alfa vs Novoseven in Congenital Factor VII Deficiency
NCT03079063Phase 3Completed
- Sponsor
- AryoGen Biopharma
- Start
- Mar 2017
- Primary completion
- Nov 2020
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 3 trial of AryoSeven in congenital factor VII deficiency, sponsored by AryoGen Biopharma. Started Mar 2017; status: completed.
02
Drugs
AryoSeven
03
Conditions
congenital factor VII deficiency
Beyond the preview
Go deeper on NCT03079063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03079063.